Annovis Bio Inc
Annovis Bio Inc (ANVS) Covered Calls
Annovis Bio Inc trades in the Biotechnology industry with an IV Rank of 85.32%, high versus the past year. ANVS's highest covered call setup is the $7.50 strike expiring Jan 21, 2028, sorted by theoretical annualized return. It's 706.45% out of the money with 434 days to expiration, a 717.20% return until expiration, and a 603.18% theoretical annualized return. Across the setups shown, annualized returns run from 30.58% to 603.18% at strikes between $1.00 and $7.50, with 154 to 798 days to expiration, as of Nov 13, 2026.
Read more
Running ANVS covered calls helps you generate income from Annovis Bio Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ANVS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ANVS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ANVS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ANVS covered call is worth writing.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia.
| 2028-01-21 | 434 | 7.50 | 706.45 | 0.10 | 2.00 | 667.00 | 717.20 | 603.18 | -10.75 | +1.00 | 30 | 1.90 |
| 2027-04-16 | 154 | 2.50 | 168.82 | 0.05 | 1.95 | 162.00 | 174.19 | 412.86 | -5.38 | +1.00 | 178 | 1.90 |
| 2027-12-17 | 399 | 2.50 | 168.82 | 0.10 | 0.50 | 167.00 | 179.57 | 164.27 | -10.75 | +0.54 | 5,371 | 0.40 |
| 2028-01-21 | 434 | 2.50 | 168.82 | 0.05 | 2.00 | 162.00 | 174.19 | 146.50 | -5.38 | +1.00 | 653 | 1.95 |
| 2027-12-17 | 399 | 2.00 | 115.05 | 0.05 | 1.50 | 112.00 | 120.43 | 110.17 | -5.38 | +0.91 | 285 | 1.45 |
| 2029-01-19 | 798 | 2.50 | 168.82 | 0.20 | 0.25 | 177.00 | 190.32 | 87.05 | -21.51 | +0.46 | 9,302 | 0.05 |
| 2027-12-17 | 399 | 1.50 | 61.29 | 0.15 | 5.00 | 72.00 | 77.42 | 70.82 | -16.13 | +1.00 | 50 | 4.85 |
| 2027-12-17 | 399 | 1.00 | 7.53 | 0.35 | 0.90 | 42.00 | 45.16 | 41.31 | -37.63 | +0.83 | 409 | 0.55 |
| 2027-04-16 | 154 | 1.00 | 7.53 | 0.05 | 1.20 | 12.00 | 12.90 | 30.58 | -5.38 | +0.83 | 88 | 1.15 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank85.32% High
- Market cap (M$)40
- 52 weeks high-83.09%
- 52 weeks low50.00%
- Analyst recommendationStrong Buy
1.00 - Target price$10.50
1300.00% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-13
- P/E—
- Future P/E—
- EPS (ttm)-1.79
- EPS growth next 5 years-2.67%
As of Nov 13, 2026